Comparative proteomics in acute myeloid leukemia

Magdalena Luczak; Maciej Kaźmierczak; Luiza Hadschuh; Krzysztof Lewandowski; Mieczysław Komarnicki; Marek Figlerowicz

doi:10.5114/wo.2012.28787

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2012
vol. 16

Send email

Copy url:

abstract:

Review paper

Comparative proteomics in acute myeloid leukemia

Magdalena Luczak

,

Maciej Kaźmierczak

,

Luiza Hadschuh

,

Krzysztof Lewandowski

,

Mieczysław Komarnicki

,

Marek Figlerowicz

Wspolczesna Onkol 2012; 16 (2): 95–103

DOI: https://doi.org/10.5114/wo.2012.28787

Online publish date: 2012/05/29

View full text Get citation

PlumX metrics:

The term proteomics was used for the first time in 1995 to describe large-scale protein analyses. At the same time proteomics was distinguished as a new domain of the life sciences. The major object of proteomic studies is the proteome, i.e. the set of all proteins accumulating in a given cell, tissue or organ. During the last years several new methods and techniques have been developed to increase the fidelity and efficacy of proteomic analyses. The most widely used are two-dimensional electrophoresis (2DE) and mass spectrometry (MS).

In the past decade proteomic analyses have also been successfully applied in biomedical research. They allow one to determine how various diseases affect the pattern of protein accumulation. In this paper, we attempt to summarize the results of the proteomic analyses of acute myeloid leukemia (AML) cells. They have increased our knowledge on the mechanisms underlying AML development and contributed to progress in AML diagnostics and treatment.

keywords:

Comparative proteomics in acute myeloid leukemia

Magdalena Luczak , Maciej Kaźmierczak , Luiza Hadschuh , Krzysztof Lewandowski , Mieczysław Komarnicki , Marek Figlerowicz

acute myeloid leukemia, proteomics, 2DE, mass spectrometry

Magdalena Luczak

,

Maciej Kaźmierczak

,

Luiza Hadschuh

,

Krzysztof Lewandowski

,

Mieczysław Komarnicki

,

Marek Figlerowicz